These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1084 related items for PubMed ID: 26935876

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
    Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S.
    Adv Ther; 2016 Sep; 33(9):1519-35. PubMed ID: 27432383
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.
    Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M.
    World J Gastroenterol; 2017 Jan 28; 23(4):668-675. PubMed ID: 28216974
    [Abstract] [Full Text] [Related]

  • 9. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW.
    Gastroenterology; 2022 Sep 28; 163(3):608-619. PubMed ID: 35679950
    [Abstract] [Full Text] [Related]

  • 10. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
    Noda H, Noguchi S, Yoshimine T, Goji S, Adachi K, Tamura Y, Izawa S, Ebi M, Yamamoto S, Ogasawara N, Funaki Y, Sasaki M, Kasugai K.
    J Gastrointestin Liver Dis; 2016 Sep 28; 25(3):283-8. PubMed ID: 27689190
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K.
    Digestion; 2018 Sep 28; 97(3):212-218. PubMed ID: 29393194
    [Abstract] [Full Text] [Related]

  • 13. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H.
    J Gastroenterol; 2020 Oct 28; 55(10):969-976. PubMed ID: 32666199
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
    Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S.
    J Gastroenterol Hepatol; 2019 Apr 28; 34(4):686-692. PubMed ID: 30151994
    [Abstract] [Full Text] [Related]

  • 15. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K.
    J Dig Dis; 2016 Oct 28; 17(10):670-675. PubMed ID: 27534444
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet; 2016 Nov 12; 388(10058):2355-2365. PubMed ID: 27769562
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.
    Liou JM, Bair MJ, Chen CC, Lee YC, Chen MJ, Chen CC, Tseng CH, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Chang WH, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hung HW, Lin JT, Chang CY, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Am J Gastroenterol; 2016 Mar 12; 111(3):381-7. PubMed ID: 26832653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.